BrainsWay Deep TMS is not currently cleared by the FDA for the safe or effective treatment of neuropathic pain. Additional outcomes from research conducted on these and other neuropathic pain patients ...

BrainsWay (BWAY) announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic ...

Participants were assigned to either an active Deep TMS or sham treatment arm for a five-day period, followed by a nine-week washout, before crossing over to the other arm. The study’s primary ...

Transcranial Magnetic Stimulation (TMS) is a non-invasive therapy that utilizes magnetic fields to stimulate nerve cells in the brain, particularly targeting regions responsible for mood ...

Treatment-resistant depression (TRD) is present in about 30.9% of individuals diagnosed with major depressive disorder in the United States (Zhdanava et al., 2021). Transmagnetic stimulation (TMS) is ...

The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major ...

We have various therapies currently approved, including electrical convulsive therapy, transcranial magnetic stimulation, and vagal nerve simulation," Espinoza said. We're still investigating the ...

Following esketamine for TRD, PHQ-9 scores significantly reduced by 5.9 in the overall cohort and 6.0 in the TMS-naïve subgroup. Sustained use of esketamine nasal spray significantly improves ...

If you have an account and are registered for online access, sign in with your email address and password below.

TMS Co., Ltd. (JP:4891) has released an update. TMS Co., Ltd. has secured a U.S. patent for a new treatment for acute kidney injury using compounds including TMS-008, further strengthening its ...